JP2012500805A5 - - Google Patents

Download PDF

Info

Publication number
JP2012500805A5
JP2012500805A5 JP2011524034A JP2011524034A JP2012500805A5 JP 2012500805 A5 JP2012500805 A5 JP 2012500805A5 JP 2011524034 A JP2011524034 A JP 2011524034A JP 2011524034 A JP2011524034 A JP 2011524034A JP 2012500805 A5 JP2012500805 A5 JP 2012500805A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
pharmaceutically acceptable
aryl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011524034A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012500805A (ja
Filing date
Publication date
Priority claimed from US12/196,516 external-priority patent/US7902187B2/en
Application filed filed Critical
Publication of JP2012500805A publication Critical patent/JP2012500805A/ja
Publication of JP2012500805A5 publication Critical patent/JP2012500805A5/ja
Pending legal-status Critical Current

Links

JP2011524034A 2008-08-22 2009-08-21 免疫抑制のための6−置換2−(ベンズイミダゾリル)プリンおよびプリノン誘導体ならびに6−置換2−(イミダゾロ[4,5−c]ピリジニル)プリンおよびプリノン誘導体 Pending JP2012500805A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/196,516 2008-08-22
US12/196,516 US7902187B2 (en) 2006-10-04 2008-08-22 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
PCT/US2009/054663 WO2010022358A1 (en) 2008-08-22 2009-08-21 6-substituted 2-(benzimidazolyl)purine and purinone derivatives and 6-substituted 2-(imidazoio[4,5- c]pyridinyl)purine and purinone derivatives for immunosuppression

Publications (2)

Publication Number Publication Date
JP2012500805A JP2012500805A (ja) 2012-01-12
JP2012500805A5 true JP2012500805A5 (https=) 2012-09-27

Family

ID=41707479

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011524034A Pending JP2012500805A (ja) 2008-08-22 2009-08-21 免疫抑制のための6−置換2−(ベンズイミダゾリル)プリンおよびプリノン誘導体ならびに6−置換2−(イミダゾロ[4,5−c]ピリジニル)プリンおよびプリノン誘導体

Country Status (5)

Country Link
US (1) US7902187B2 (https=)
EP (1) EP2326647A4 (https=)
JP (1) JP2012500805A (https=)
CA (1) CA2735048A1 (https=)
WO (1) WO2010022358A1 (https=)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2577514T3 (es) * 2005-08-22 2016-07-15 The Regents Of The University Of California Antagonistas de TLR
WO2007030438A2 (en) * 2005-09-06 2007-03-15 Pharmacopeia, Inc. Aminopurine derivatives for treating neurodegenerative diseases
US20070253896A1 (en) * 2006-02-07 2007-11-01 Conforma Therapeutics Corporation 7,9-Dihydro-Purin-8-One and Related Analogs as HSP90-Inhibitors
US20090281075A1 (en) * 2006-02-17 2009-11-12 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
US7989459B2 (en) * 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
CA2646429A1 (en) * 2006-03-09 2007-09-13 Pharmacopeia, Inc. 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders
EP2029597A4 (en) * 2006-05-31 2011-11-23 Univ California purine analogs
US7767685B2 (en) * 2006-06-29 2010-08-03 King Pharmaceuticals Research And Development, Inc. Adenosine A2B receptor antagonists
TW200837064A (en) * 2006-10-04 2008-09-16 Pharmacopeia Inc 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression
TW200831104A (en) * 2006-10-04 2008-08-01 Pharmacopeia Inc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7902187B2 (en) 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7968556B2 (en) * 2006-10-19 2011-06-28 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and methods of treatment therewith
US20080119496A1 (en) * 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
ES2552471T3 (es) 2007-02-07 2015-11-30 The Regents Of The University Of California Conjugados de agonistas de TLR sintéticos y usos de los mismos
BRPI0817503B8 (pt) * 2007-10-05 2021-05-25 Sstarbio Pte Ltd derivados de purina substituídos por pirimidina, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para a prevenção ou tratamento de uma condição proliferativa
EA201001264A1 (ru) * 2008-02-07 2011-04-29 Дзе Регентс Оф Дзе Юниверсити Оф Калифорния Способ лечения заболеваний мочевого пузыря с помощью активатора tlr7
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
KR20110117705A (ko) * 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
MY177695A (en) 2009-10-26 2020-09-23 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds
UA109775C2 (xx) * 2009-10-29 2015-10-12 N-вмісні гетероарильні похідні як інгібітори jak3-кінази
TW201144310A (en) * 2010-04-28 2011-12-16 Daiichi Sankyo Co Ltd [5,6] heterocyclic compound
NZ603155A (en) 2010-04-30 2014-06-27 Telormedix Sa Phospholipid drug analogs
US9050319B2 (en) 2010-04-30 2015-06-09 Telormedix, Sa Phospholipid drug analogs
KR101978537B1 (ko) 2011-10-19 2019-05-14 시그날 파마소티칼 엘엘씨 Tor 키나제 억제제를 사용한 암의 치료
JP6076370B2 (ja) 2011-12-02 2017-02-08 シグナル ファーマシューティカルズ,エルエルシー 7−(6−(2−ヒドロキシプロパン−2−イル)ピリジン−3−イル)−1−((トランス)−4−メトキシシクロヘキシル)−3,4−ジヒドロピラジノ[2,3−b]ピラジン−2(1H)−オンの薬剤組成物、その固体形態、およびその使用方法
TWI615143B (zh) 2012-02-24 2018-02-21 標誌製藥公司 使用tor激酶抑制劑組合療法以治療癌症之方法
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
EP2945636B1 (en) 2013-01-16 2017-06-28 Signal Pharmaceuticals, LLC Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
AU2014254052B2 (en) 2013-04-17 2019-06-06 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
BR112015026297B1 (pt) 2013-04-17 2022-08-23 Signal Pharmaceuticals, Llc Uso de um inibidor da quinase tor e quinazolinona 5-substituída, composição farmacêutica que os compreende, e kit
TW201527300A (zh) 2013-04-17 2015-07-16 Signal Pharm Llc 關於1-乙基-7-(2-甲基-6-(1H-1,2,4-三唑-3-基)吡啶-3-基)-3,4-二氫吡并[2,3-b]吡-2(1H)-酮之醫藥調配物、方法、固態型式及使用方法
US9782427B2 (en) 2013-04-17 2017-10-10 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
TW201521725A (zh) 2013-04-17 2015-06-16 Signal Pharm Llc 使用tor激酶抑制劑組合療法以治療癌症之方法
BR112015026292B1 (pt) 2013-04-17 2022-04-12 Signal Pharmaceuticals, Llc Uso de 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-il)piridin-3-il)-3,4-dihidropirazino [2,3-b]pirazin-2(1h)- ona e métodos in vitro
US9937169B2 (en) 2013-04-17 2018-04-10 Signal Pharmaceuticals, Llc Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
EP3003313A1 (en) 2013-05-29 2016-04-13 Signal Pharmaceuticals, LLC Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
EP3131552B1 (en) 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Methods for treating cancer using tor kinase inhibitor combination therapy
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
EA201790189A1 (ru) 2014-07-14 2017-11-30 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе
US10183949B2 (en) 2014-08-29 2019-01-22 The University Of Tokyo Pyrimidinone derivative having autotaxin-inhibitory activity
WO2017133657A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza
WO2017133664A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Bicyclic pyridine and pyrimidine derivatives and their use in the treatment, amelioration or prevention of influenza
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
SMT202100225T1 (it) * 2016-12-20 2021-05-07 Astrazeneca Ab Composti di ammino-triazolopiridina e loro uso nel trattamento del cancro
EP3641772B1 (en) 2017-06-22 2023-08-02 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
CN117751127A (zh) * 2021-08-20 2024-03-22 南京大美生物制药有限公司 一种五元含氮杂环并杂芳基类衍生物及其用途
WO2025234404A1 (ja) * 2024-05-07 2025-11-13 全薬工業株式会社 ピリミジン含有縮合環化合物及びその用途

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES473201A1 (es) 1977-09-26 1979-03-16 Degussa Procedimiento para la preparacion de 7-azabencimidazoles
US4813998A (en) 1986-02-27 1989-03-21 Janssen Pharmaceutica N.V. Herbicidal 1H-imidazole-5-carboxylic acid derivatives
EP0277384A3 (en) 1986-12-24 1990-05-23 Janssen Pharmaceutica N.V. 1h-imidazole-5-carboxylic acid derivatives
DE4007535A1 (de) 1990-03-09 1991-09-12 Hoechst Ag Wasserunloesliche azofarbmittel, ihre herstellung und verwendung
JP3396924B2 (ja) 1993-09-07 2003-04-14 日本曹達株式会社 活性汚泥のバルキング防止剤
US5705625A (en) 1994-12-15 1998-01-06 The Johns Hopkins University School Of Medicine Nucleic Acid Encoding novel protein tyrosine kinase
CN1207735A (zh) 1995-11-27 1999-02-10 出光兴产株式会社 三嗪衍生物
AR007115A1 (es) 1996-05-15 1999-10-13 Hoechst Ag Cromanos sustituidos con sulfonamida, procedimiento para su preparacion, su empleo para la preparacion de medicamento o agente de diagnostico, asi como medicamento que los contiene
US6432947B1 (en) 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
WO2000012089A1 (en) 1998-08-31 2000-03-09 Merck & Co., Inc. Novel angiogenesis inhibitors
WO1999024432A1 (fr) 1997-11-12 1999-05-20 Mitsubishi Chemical Corporation Derives de purine et medicament les renfermant en tant qu'ingredient actif
ZA9810490B (en) 1997-12-03 1999-05-20 Dainippon Pharmaceutical Co 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
JP2002503659A (ja) 1998-02-13 2002-02-05 アベンテイス・フアルマ・ソシエテ・アノニム 縮合した複素環式系誘導体、それらの製造及びそれらを含有する製薬学的組成物
US6313129B1 (en) 1998-08-21 2001-11-06 Hughes Institute Therapeutic compounds
US6080747A (en) 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
US6841549B1 (en) 1999-07-02 2005-01-11 Eisai Co., Ltd. Condensed imidazole compounds and a therapeutic agent for diabetes mellitus
PL354241A1 (en) 1999-09-17 2003-12-29 Abbott Gmbh & Co.Kgabbott Gmbh & Co.Kg Kinase inhibitors as therapeutic agents
US6582357B2 (en) 2000-05-24 2003-06-24 Pentax Corporation Treating instrument erecting device for use in endoscope
US6506738B1 (en) 2000-09-27 2003-01-14 Bristol-Myers Squibb Company Benzimidazolone antiviral agents
GB0100623D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
AR035230A1 (es) 2001-03-19 2004-05-05 Astrazeneca Ab Compuestos de bencimidazol, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion farmaceutica, y usos de estos compuestos para la elaboracion de medicamentos
SE0104331D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Novel compounds
CA2501940A1 (en) 2002-10-09 2004-04-22 Tolerrx, Inc. Molecules preferentially associated with effector t cells or regulatory t cells and methods of their use
CA2505546A1 (en) 2002-11-08 2004-05-27 Tolerrx, Inc. Molecules preferentially associated with effector t cells and methods of their use
NZ539901A (en) 2002-11-26 2007-09-28 Pfizer Prod Inc Method of treatment of transplant rejection
JP2004217582A (ja) 2003-01-16 2004-08-05 Abbott Japan Co Ltd 9h−プリン誘導体
KR101224300B1 (ko) 2003-02-05 2013-01-21 바이엘 크롭사이언스 아게 키랄 바이사이클릭 라디칼로 n-치환된 아미노 1,3,5-트라이아진, 이것의 제조방법, 이것의 조성물 및 제초제 및 식물 성장 조절제로서의 이것의 용도
SE0301373D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
US7749999B2 (en) 2003-09-11 2010-07-06 Itherx Pharmaceuticals, Inc. Alpha-ketoamides and derivatives thereof
NZ546058A (en) 2004-01-12 2010-09-30 Ym Biosciences Australia Pty Benzimidazole and other fused ring derivatives as selective janus kinase inhibitors
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
EP1846408B1 (en) 2005-01-14 2013-03-20 Janssen Pharmaceutica NV 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
CA2596830A1 (en) 2005-02-03 2006-09-14 Vertex Pharmaceuticals Incorporated Pyrrolopyrimidines useful as inhibitors of protein kinase
CA2598076A1 (en) 2005-02-16 2006-08-24 Astrazeneca Ab Chemical compounds
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
US7884109B2 (en) * 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
NZ562468A (en) * 2005-04-05 2009-10-30 Pharmacopeia Inc Purine and imidazopyridine derivatives for immunosuppression
DE102005042742A1 (de) 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
US20090023723A1 (en) * 2005-09-21 2009-01-22 Pharmacopeia Drug Discovery, Inc. Purinone derivatives for treating neurodegenerative diseases
WO2007058990A2 (en) 2005-11-14 2007-05-24 Kemia, Inc. Therapy using cytokine inhibitors
US20070253896A1 (en) * 2006-02-07 2007-11-01 Conforma Therapeutics Corporation 7,9-Dihydro-Purin-8-One and Related Analogs as HSP90-Inhibitors
US7989459B2 (en) * 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
US20090281075A1 (en) 2006-02-17 2009-11-12 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
CA2691214A1 (en) 2006-06-09 2007-12-21 Kemia, Inc. Therapy using cytokine inhibitors
TW200837064A (en) * 2006-10-04 2008-09-16 Pharmacopeia Inc 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression
TW200831104A (en) * 2006-10-04 2008-08-01 Pharmacopeia Inc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7902187B2 (en) 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7968556B2 (en) 2006-10-19 2011-06-28 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and methods of treatment therewith
ATE543819T1 (de) 2006-10-19 2012-02-15 Signal Pharm Llc Heteroarylverbindungen, zusammensetzungen daraus und behandlungsverfahren damit
US20080119496A1 (en) * 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
US20080220256A1 (en) * 2007-03-09 2008-09-11 Ues, Inc. Methods of coating carbon/carbon composite structures
TW200902025A (en) * 2007-04-11 2009-01-16 Alcon Res Ltd Use of an inhibitor of TNF α plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
CA2686485A1 (en) 2007-05-23 2008-11-27 Pharmacopeia, Llc Purinones and 1h-imidazopyridinones as pkc-theta inhibitors
WO2009062059A2 (en) 2007-11-08 2009-05-14 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors

Similar Documents

Publication Publication Date Title
JP2012500805A5 (https=)
AU2018236691B2 (en) N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
HRP20211973T1 (hr) Kinazolini kao inhibitori ionskih kalijskih kanala
JP2016540742A5 (https=)
JP2022137047A5 (https=)
JP2013514980A5 (https=)
JP2013543842A5 (https=)
JP2013536235A5 (https=)
JP2013542994A5 (https=)
JP2013505929A5 (https=)
JP2019519587A5 (https=)
JP2016503785A5 (https=)
NZ603427A (en) 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace)
JP2010504286A5 (https=)
HK1201519A1 (en) Inhibitors of phosphodiesterase type 10a
MX2009008509A (es) Compuesto de anillo puenteado-aza.
JP2016501185A5 (https=)
JP2009235100A5 (https=)
JP2015504091A5 (https=)
JP2016513108A5 (ja) 治療用化合物
JP2015529681A5 (https=)
JP2015508092A5 (https=)
JP2007522142A5 (https=)
JP2016513648A5 (https=)
JP2019532974A5 (https=)